Table 4 Drug-pathway association in the DTPN of basal BC subtype
Drug | Pathway | NE | nNE and PCI (vs NE = 0.3445) |
|---|---|---|---|
Fluorouracil | Aryl hydrocarbon receptor signaling (1); salvage pathways of pyrimidine deoxyribonucleotides (2) | 0.3445 | (1) 0.3241 (PCI 5.9%) (2) 0.3425 (PCI 0.56%) (1–2) 0.3208 (PCI 6.86%) |
Capecitabine | Triacylglycerol degradation | 0.3445 | 0.3429 (PCI 0.46%) |
Fulvestrant | Aryl hydrocarbon receptor signaling | 0.3445 | 0.3241 (PCI 5.9%) |
Methotrexate | Salvage pathways of pyrimidine deoxyribonucleotides | 0.3445 | 0.3425 (PCI 0.56%) |
Raloxifene | Aryl hydrocarbon receptor signaling | 0.3445 | 0.3241 (PCI 5.9%) |
Tamoxifene | Aryl hydrocarbon receptor signaling | 0.3445 | 0.3241 (PCI 5.9%) |